source
- Sanofi beats Q1 sales forecasts, driven by strong Dupixent demandSanofi reported first‑quarter results that exceeded Wall Street expectations, with net sales rising 6.2% to €10.5 billion (about $12.3 billion).\n\nThe growth was led by Dupixent, the anti‑inflamma…
- Roche eyes up to $9 billion annual sales from breast cancer pill and obesity drug pipeline amid biosimilar pressureRoche reported first‑quarter earnings that showed a 5% dip in reported revenue, driven by a weaker U.S. dollar against the Swiss franc. On a constant‑currency basis, sales rose 6% to 14.7 billion S…